Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
Open Access
- 8 May 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 4 (5) , 1227-1239
Abstract
The most common oncogenic driver mutations for non–small cell lung cancer (NSCLC) activate EGFR or KRAS. Clinical trials exploring treatments for EGFR- or KRAS-mutated (EGFRmut or KRASmut) cancers have focused on small-molecule inhibitors targeting the driver mutations. Typically, these inhibitors perform more effectively based on combination with either chemotherapies, or other targeted therapies. For EGFRmut NSCLC, a combination of inhibitors of EGFR and Aurora-A kinase (AURKA), an oncogene commonly overexpressed in solid tumors, has shown promising activity in clinical trials. Interestingly, a number of recent studies have indicated that EGFR activity supports overall viability of tumors lacking EGFR mutations, and AURKA expression is abundant in KRASmut cell lines. In this study, we have evaluated dual inhibition of EGFR and AURKA in KRASmut NSCLC models. These data demonstrate synergy between the EGFR inhibitor erlotinib and the AURKA inhibitor alisertib in reducing cell viability and clonogenic capacity in vitro, associated with reduced activity of EGFR pathway effectors, accumulation of enhanced aneuploid cell populations, and elevated cell death. Importantly, the erlotinib-alisertib combination also synergistically reduces xenograft growth in vivo. Analysis of signaling pathways demonstrated that the combination of erlotinib and alisertib was more effective than single-agent treatments at reducing activity of EGFR and pathway effectors following either brief or extended administration of the drugs. In sum, this study indicates value of inhibiting EGFR in KRASmut NSCLC, and suggests the specific value of dual inhibition of AURKA and EGFR in these tumors. Significance: The introduction of specific KRAS G12C inhibitors to the clinical practice in lung cancer has opened up opportunities that did not exist before. However, G12C alterations are only a subtype of all KRAS mutations observed. Given the high expression of AURKA in KRASmut NSCLC, our study could point to a potential therapeutic option for this subgroup of patients.Keywords
All Related Versions
Funding Information
- HHS | NIH | National Cancer Institute (P30 CA006927)
- William Wikoff Smith Charitable Trust
This publication has 67 references indexed in Scilit:
- Mechanisms of tumor resistance to EGFR-targeted therapiesExpert Opinion on Therapeutic Targets, 2009
- Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male miceCancer Chemotherapy and Pharmacology, 2007
- Constitutive Phosphorylation of Aurora-A on Ser51 Induces Its Stabilization and Consequent Overexpression in CancerPLOS ONE, 2007
- High copy amplification of the aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancersCancer Biology & Therapy, 2007
- Mutation analysis of 24 known cancer genes in the NCI-60 cell line setMolecular Cancer Therapeutics, 2006
- HEF1-Aurora A Interactions: Points of Dialog between the Cell Cycle and Cell Attachment Signaling NetworksCell Cycle, 2006
- The ErbB/HER receptor protein-tyrosine kinases and cancerBiochemical and Biophysical Research Communications, 2004
- AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to TaxolCancer Cell, 2003
- FAK integrates growth-factor and integrin signals to promote cell migrationNature Cell Biology, 2000
- c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor FunctionJournal of Biological Chemistry, 1999